FDA and CMS move to head off state-federal clash over clinical AI rules

· Health · United States

US officials are moving behind the scenes to prevent a regulatory conflict between states and the federal government over how artificial intelligence is regulated in clinical settings, STAT+ reports. The concern is a regulatory logjam as more states look to test AI in clinical care. The FDA and CMS are working to coordinate as state-level initiatives proliferate. The report does not detail specific proposals. The effort reflects growing tension over who governs AI tools used in diagnosis and treatment, and signals that federal agencies want a coherent framework before state rules multiply.

Why it matters：Divergent state and federal rules for clinical AI could fragment the market for medical AI tools, affecting developers and providers alike.

Key points

  • FDA and CMS officials are working behind the scenes on coordination.
  • More states are looking to test AI in clinical settings.
  • The report did not detail specific regulatory proposals.

Sources (original reporting)

More stories from this day